Shanghai Dino Pharmaceutical Technology

Shanghai Dino Pharmaceutical Technology is a China-based biotechnology company specializing in the discovery and development of innovative small molecule therapeutics for autoimmune diseases and oncology. The company is best known for its expertise in structure-based drug design, which led to the development of its lead asset, DN011 (also known as SIM0335), a highly selective Tyrosine kinase 2 (TYK2) inhibitor. In May 2021, the company was acquired by Simcere Pharmaceutical Group for approximately 800 million RMB to bolster Simcere's immunology pipeline and R&D capabilities. Dino Pharmaceutical now operates as a specialized research unit within the Simcere ecosystem, focusing on next-generation kinase inhibitors and other high-value small molecule targets. Its lead programs are currently advancing through Phase 2 clinical trials for indications such as psoriasis and atopic dermatitis.